Synonyms
Acceleration; Blast crisis; Blast phase; Spent phase
Definition
Myeloproliferative neoplasms, including chronic myeloid leukemia (CML) and polycythemia vera (PV), may progress from a steady-state phase (chronic phase) with sufficient production of mature blood cells to an accelerated phase with deterioration of hematologic blood parameters and/or organomegaly. Chronic and accelerated phase may be followed by a blast phase with more than 20% immature blasts in the blood or bone marrow. Transition from chronic to accelerated and blast phase, respectively, is defined by varying parameters, which according to WHO (Vardiman et al. 2017) are summarized in Table 1.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References and Further Reading
Baccarani, M., Cortes, J., Pane, F., Niederwieser, D., Saglio, G., Apperley, J., Cervantes, F., Deininger, M., Gratwohl, A., Guilhot, F., Hochhaus, A., Horowitz, M., Hughes, T., Kantarjian, H., Larson, R., Radich, J., Simonsson, B., Silver, R. T., Goldman, J., Hehlmann, R., & LeukemiaNet, E. (2009). Chronic myeloid leukemia: An update of concepts and management recommendations of European LeukemiaNet. Journal of Clinical Oncology, 27, 6041–6051.
Baccarani, M1., Castagnetti, F., Gugliotta, G., Palandri, F., & Rosti, G. (2014). Definition and treatment of resistance to tyrosine kinase inhibitors in chronic myeloid leukemia. Expert Review of Hematology, 7, 397–406.
Barosi, G., Mesa, R. A., Thiele, J., Cervantes, F., Campbell, P. J., Verstovsek, S., Dupriez, B., Levine, R. L., Passamonti, F., Gotlib, J., Reilly, J. T., Vannucchi, A. M., Hanson, C. A., Solberg, L. A., Orazi, A., Tefferi, A., & International Working Group for Myelofibrosis Research and Treatment (IWG-MRT). (2008). Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: A consensus statement from the International Working Group for Myelofibrosis Research and Treatment. Leukemia, 22, 437–438.
Bartels, S., Lehmann, U., Büsche, G., Schlue, J., Mozer, M., Stadler, J., Triviai, I., Alchalby, H., Kröger, N., & Kreipe, H. (2015). SRSF2 and U2AF1 mutations in primary myelofibrosis are associated with JAK2 and MPL but not calreticulin mutation and may independently reoccur after allogeneic stem cell transplantation. Leukemia, 29, 253–255.
Bartels, S., Faisal, M., Büsche, G., Schlue, J., Kreipe, H., & Lehmann, U. (2018). Fibrotic progression in Polycythemia vera is associated with early concomitant driver-mutations besides JAK2. Leukemia, 32, 556–558.
Deininger, M. W. (2015). Diagnosing and managing advanced chronic myeloid leukemia. American Society of Clinical Oncology Educational Book, e381-8. https://doi.org/10.14694/EdBook_AM.2015.35.e381
Hehlmann, R., Saußele, S., Voskanyan, A., & Silver, R. T. (2016). Management of CML-blast crisis. Best Practice & Research. Clinical Haematology, 29, 295–307.
Hussein, K., Bock, O., Seegers, A., Flasshove, M., Henneke, F., Buesche, G., & Kreipe, H. H. (2007). Myelofibrosis evolving during imatinib treatment of a chronic myeloproliferative disease with coexisting BCR-ABL translocation and JAK2V617F mutation. Blood, 9, 4106–4107.
Kantarjian, H. M., Dixon, D., Keating, M. J., Talpaz, M., Walters, R. S., McCredie, K. B., & Freireich, E. J. (1988). Characteristics of accelerated disease in chronic myelogenous leukemia. Cancer, 61, 1441–1446.
Khalidi, H. S., Brynes, R. K., Medeiros, L. J., Chang, K. L., Slovak, M. L., Snyder, D. S., & Arber, D. A. (1998). The immunophenotype of blast transformation of chronic myelogenous leukemia: A high frequency of mixed lineage phenotype in "lymphoid" blasts and A comparison of morphologic, immunophenotypic, and molecular findings. Modern Pathology, 11, 1211–1221.
Lehmann, U., Bartels, S., Hasemeier, B., Geffers, R., Schlue, J., Büsche, G., Hussein, K., & Kreipe, H. (2013). SRSF2 mutation is present in the hypercellular and prefibrotic stage of primary myelofibrosis. Blood, 121, 4011–4012.
Lundberg, P., Karow, A., Nienhold, R., Looser, R., Hao-Shen, H., Nissen, I., Girsberger, S., Lehmann, T., Passweg, J., Stern, M., Beisel, C., Kralovics, R., & Skoda, R. C. (2014). Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms. Blood, 123, 2220–2228.
Mesa, R. A., Verstovsek, S., Cervantes, F., Barosi, G., Reilly, J. T., Dupriez, B., Levine, R., Le Bousse-Kerdiles, M. C., Wadleigh, M., Campbell, P. J., Silver, R. T., Vannucchi, A. M., Deeg, H. J., Gisslinger, H., Thomas, D., Odenike, O., Solberg, L. A., Gotlib, J., Hexner, E., Nimer, S. D., Kantarjian, H., Orazi, A., Vardiman, J. W., Thiele, J., Tefferi, A., & International Working Group for Myelofibrosis Research and Treatment (IWG-MRT). (2007). Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): Consensus on terminology by the international working group for myelofibrosis research and treatment (IWG-MRT). Leukemia Research, 31, 737–740.
Mukherjee, S., & Kalaycio, M. (2016). Accelerated phase CML: outcomes in newly diagnosed vs. progression from chronic phase. Curr Hematol Malig Rep, 11:86–93.
Ortmann, C. A., Kent, D. G., Nangalia, J., Silber, Y., Wedge, D. C., Grinfeld, J., Baxter, E. J., Massie, C. E., Papaemmanuil, E., Menon, S., Godfrey, A. L., Dimitropoulou, D., Guglielmelli, P., Bellosillo, B., Besses, C., Döhner, K., Harrison, C. N., Vassiliou, G. S., Vannucchi, A., Campbell, P. J., & Green, A. R. (2015). Effect of mutation order on myeloproliferative neoplasms. The New England Journal of Medicine, 372, 601–612.
Reid, A. G., De Melo, V. A., Elderfield, K., Clark, I., Marin, D., Apperley, J., & Naresh, K. N. (2009). Phenotype of blasts in chronic myeloid leukemia in blastic phase-Analysis of bone marrow trephine biopsies and correlation with cytogenetics. Leukemia Research, 33, 418–425.
Silverstein, M. N. (1976). The evolution into and the treatment of late stage polycythemia vera. Seminars in Hematology, 13, 79–84.
Soverini, S., Hochhaus, A., Nicolini, F. E., Gruber, F., Lange, T., Saglio, G., Pane, F., Müller, M. C., Ernst, T., Rosti, G., Porkka, K., Baccarani, M., Cross, N. C., & Martinelli, G. (2011). BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: Recommendations from an expert panel on behalf of European LeukemiaNet. Blood, 118, 1208–1215.
Steegmann, J. L., Baccarani, M., Breccia, M., Casado, L. F., GarcÃa-Gutiérrez, V., Hochhaus, A., Kim, D. W., Kim, T. D., Khoury, H. J., Le Coutre, P., Mayer, J., Milojkovic, D., Porkka, K., Rea, D., Rosti, G., Saussele, S., Hehlmann, R., & Clark, R. E. (2016). European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia. Leukemia, 30, 1648–1671.
Vannucchi, A. M., & Harrison, C. N. (2017). Emerging treatments for classical myeloproliferative neoplasms. Blood, 129, 693–703.
Vardiman JW, Melo JV, Baccarani M, Radich JP, Kvasnicka HM (2017) Chronic myelogenous leukemia, BCR-ABL1 positive. In: WHO classification of haematopoietic and lymphoid tissues SH Swerdlow, E Campo, N Lee Harris, ES Jaffe, SA Pileri, H Stein, J Thiele, DA Arber, Hasserjian RP, LeBeau MM, Orazi A, Siebert R, pp. 30–36. IARC Press, Lyon.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2020 Springer Nature Switzerland AG
About this entry
Cite this entry
Kreipe, H.H. (2020). Chronic Myeloid Leukemia, Polycythemia Vera Progression. In: Molina, T.J. (eds) Hematopathology. Encyclopedia of Pathology. Springer, Cham. https://doi.org/10.1007/978-3-319-95309-0_3858
Download citation
DOI: https://doi.org/10.1007/978-3-319-95309-0_3858
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-95308-3
Online ISBN: 978-3-319-95309-0
eBook Packages: MedicineReference Module Medicine